1\ Endotheliopathy in COVID-19 Associated Coagulopathy. Where is the field now and where is it moving in its treatment? A thread on behalf of the multidisciplinary work @YaleMedicine published just now @TheLancetHaem. 2\ What is known before our study: DD and fibrinogen are often sky high. Clinically we see thrombosis in 3 forms: macrovascular, microvascular and arterial. The former two at alarming rates in some studies, see below from our late breaking oral #EHA25virtual.

1/ #COVID19 #Tweetorial, calling #MedStudentTwitter / #medtwitter to help search the literature as we refine treatment protocols @YaleMedicine @The_BMC @Pranay_md @KaminskiMed for the benefit of all.

Background: We need to tackle antiviral and hyperinflammation pathoimmunology 2/ Given no known efficient therapy, chloroquine was investigated given its prior described inhibition of several coronaviruses. This became a backbone of therapy (pubmed.ncbi.nlm.nih.gov/32171740/). Chloroquine is not readily available in the US at this time.